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ABSTRACT
BACKGROUND: Protecting the skin against moisture-associated
damage is an important component of comprehensive skin and
wound care. Based on a review of literature, the authors propose
key interventions to protect and prevent damage in the skin folds,
perineum, and areas surrounding a wound or stoma.
OBJECTIVE: The aim of this scoping review is to identify and provide a
narrative integration of the existing evidence related to themanagement
and prevention of moisture-associated skin damage (MASD).
METHODS: Study authors searched several databases for a broad
spectrum of published and unpublished studies in English, published
between 2000 and July 2015. Selected study information was
collated in several different formats; ultimately, key findings were
aggregated into a thematic description of the evidence to help
generate a set of summative statements or recommendations.
RESULTS: Based on inclusion criteria, 37 articles were
considered appropriate for this review. Findings included
functional definitions and prevalence rates of the 4 types of
MASD, assessment scales for each, and 7 evidence-based
strategies for the management of MASD.
CONCLUSIONS: Based on this scoping review of literature, the authors
propose key interventions to protect and prevent MASD including the
use of barrier ointments, liquid polymers, and cyanoacrylates to create
a protective layer that simultaneously maintains hydration levels while
blocking external moisture and irritants.
KEYWORDS: moisture-associated skin damage, skin damage,
incontinence-associated dermatitis, irritant contact dermatitis,
scoping review, intertriginous dermatitis
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INTRODUCTION
Among many vital functions, the skin functions as a barrier to
protect the body against mechanical trauma, noxious irritants,
infectious pathogens, and excessive fluids. Overexposure of the
skin to moisture can compromise the integrity of the barrier,
disrupting the intricate molecular arrangement of intercellular
lipids in the stratum corneum and the intercellular connections be-
tween epidermal cells (corneocytes). Once damaged, the skin is
more permeable and susceptible to irritant penetration, leading
to inflammation or dermatitis. Further, wet skin has a high coeffi-
cient of friction,making it susceptible to friction and shear damage.
The term moisture-associated skin damage (MASD) delineates a
spectrum of injury characterized by the inflammation and erosion
(or denudation) of the epidermis resulting from prolonged expo-
sure to various sources of moisture and potential irritants (eg,
urine, stool, perspiration, wound exudate, and ostomy effluent).1
Technically, MASD is a type of irritant contact dermatitis, but it
is an umbrella term that includes 4 distinct clinical entities:
incontinence-associated dermatitis (IAD), intertriginous der-
matitis (ITD), periwound skin damage, and peristomal MASD.1
Moisture-associated skin damage is a complex, heterogeneous
condition. With the shift in demographic toward an aging popu-
lation worldwide, MASD is an increasingly common condition
that places a significant burden on patients and the health sys-
tem.1 Patients with MASD experience intense, persistent symp-
toms such as pain, burning, and pruritus, especially where skin
breakdown involves partial-thickness erosions and denudement.
Emerging evidence highlights the association between MASD
and other skin conditions such as dermatitis, cutaneous fungal/
bacterial infection, and pressure injuries.2,3
The development and severity of MASD depend on a number
of intrinsic and extrinsic factors. It is common among individuals
with excessive perspiration, increased dermal metabolism (ie,
elevated local temperature), abnormal skin pH, history of atopy
(ie, genetic susceptibility to contaminants/irritants), deep body
folds, dermal atrophy, and inadequate sebum production.1,4
Extrinsic factors that may precipitate and exacerbate MASD
are chemical/biologic irritants, mechanical stress on the skin
(eg, friction, pressure, shear), fungal/candidiasis proliferation,
seasonal or environmental factors (eg, humidity), incontinence
(urine, fecal, or both), and hygienic practices.4
Prevention and treatment of MASD may encompass a variety
of options including specialized equipment or surfaces, inconti-
nence products, customized linen and fabrics, dressings, and skin
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cleansing agents, in addition to topical application of barriers and
moisturizers to protect or strengthen the skin. It is important to
implement cost-effective evidence-based practices to prevent
and treat MASD; therefore, this article presents a scoping review
of management strategies and interventions for preventing or
treating MASD across the continuum of care.
Aim
The aim of this scoping review is to identify and provide a narra-
tive integration of the existing evidence related to themanagement
and prevention of MASD. A scoping review is a form of knowl-
edge synthesis used to map key concepts, types of evidence, and
gaps in research to inform policymakers, practitioners, and patients.
METHODS
This scoping review follows the methodology proposed by
Arksey andO’Malley5 to helpmap, review, and synthesize a wide
range of existing evidence. Unlike systematic reviews, a scoping
review does not involve detailed critical appraisal of individual
studies.
Inclusion Criteria
This review included abroad spectrumof published andunpublished
studies encompassing meta-analysis, randomized controlled tri-
als (RCTs), case-control studies, case series, and case studies that
evaluated interventions to prevent or manage MASD and related
conditions in any setting, on any clinical population, of any age.
Only studies published in English were considered. Opinion
papers, commentaries, and editorials were excluded from this
scoping review to minimize bias. Studies published from 2000
to July 2015 were considered for inclusion.
An initial search of MEDLINE and CINAHL was undertaken
by the authors followed by an analysis of titles and abstracts
and of the index terms used to describe each article.With the help
of a science librarian, a second search using all identified key-
words and index terms was undertaken across several databases:
the Cochrane Database of Systematic Reviews, the Joanna Briggs
Institute, the Effective Practice and Organization of Care data-
base, CINAHL, MEDLINE, EMBASE, and the Health Technology
Assessment database. Search strategies involved using the fol-
lowing keywords: moisture, skin damage, exudate, intertrigo,
ITD, IAD, MASD, and periwound, ostomy, and stoma. The ref-
erence lists of all identified articles were searched for additional
studies to include.
Study Selection
Two reviewers independently reviewed each title and abstract
of the literature search results to determine whether the article
should receive amore in-depth review. Reviewerswere instructed
to include articles evenwhen there was insufficient information to
determine the relevance. When disagreements on study inclusion
emerged, discrepancies were resolved through discussion.
Collating, Summarizing, and Reporting the Results
Relevant information was extracted from selected articles using
a standardized abstraction form to document author names,
the purpose of the study/paper, types of participants, research
methods, study setting, outcome and assessment details, con-
clusions, and implications for practice.
The number of studies and their characteristicsVincluding
study design, year of publication, type(s) of interventions, study
population, and key findingsVare summarized in Supplemental
Digital Content 1, http://links.lww.com/NSW/A9.
A summary of key findings and proposed recommendations
also were compiled into a topic matrix to allow easy comparison
by topic and strength of evidence.
In the final synthesis of this scoping review, key findings were
aggregated into a thematic description of the evidence to help
generate a set of summative statements or recommendations.
RESULTS
The initial literature search yielded 283 articles. Based on the in-
clusion criteria, 37 articles were considered appropriate for the
review.2,6Y41 Of all the selected articles, 15 studies evaluated the
management/prevention of IAD, 15 studies addressed periwound
skin damage, 2 studies addressed peristomal MASD, and 5 were
miscellaneous studies. Various study designs were included: 15
RCTs, 12 quasi-experimental studies, 6 prospective observational
studies, 3 case studies, and 1 meta-analysis.
Together, the findings from these articles provided functional
definitions and prevalence rates of the 4 types of MASD, assess-
ment scales for each, and 7 evidence-based strategies for the
management of MASD.
Defining MASD
1. Incontinence-Associated Dermatitis
The ammonia in urine and/or stool creates an alkaline environ-
ment that potentiates the proteolytic activity of fecal enzymes
(protease and lipase) on skin, leading to IAD. These enzymes dis-
rupt the skin acid mantle, making it easy for irritants to penetrate
into the skin and trigger an inflammatory response. Current esti-
mates of IAD prevalence ranges from 5.6% to 50% across differ-
ent healthcare settings, patient populations, and age groups; it is
highest among critically ill patients.42
Growing attention is being paid to the relationship between
IAD and pressure injury development. A study using the Mini-
mumData Set showed that individuals with frequent bowel con-
tinence (odds ratio, 4.15; 95% confidence interval [CI], 4.07Y4.23)
were 4.15 times more likely to develop pressure ulcers (95% CI,
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4.07Y4.23).43 In a recent systematic review and meta-analysis,
Beeckman et al44 confirmed that individuals with bowel and
bladder incontinence and related IAD are 4.99 times more likely
(95% CI, 2.62Y9.50) to develop pressure ulcers than those who
are continent.
2. Intertriginous Dermatitis
Also called intertrigo, ITD is a type of moisture-related skin dam-
age between skin folds, commonly found in the inframammary,
pannus, groin, perianal, and interdigital areas. The combination
of excess moisture from perspiration, occlusion with limited air
flow, and friction between the opposing epidermal surfaces can
lead to ITD.45,46 Intertriginous dermatitis is initially characterized
bymirror-image erythema, inflammation, and peripheral scaling,
but over time the epidermis can become macerated, edematous,
crusted, and eroded and provide an optimal environment for
the proliferation of microorganisms such as Candida albicans that
can cause secondary infections.45Y47
Based on current understanding of the pathophysiology that
underlies ITD, a number of risk factors have been considered
including hyperhidrosis, immunodeficiency, diabetes mellitus,
immobility, large skin folds, and obesity.45Y47 The prevalence
of ITD varies by context: 6% in acute care, 17% in long-term
care, and 20% in community dwellings.48
3. Periwound Skin Damage
While moisture is essential to promote wound healing, wound
fluid contains endogenous protein-degrading enzymes that are
caustic and damaging to the intact skin.49,50 Periwound skin is
particularly vulnerable to MASD when drainage volume exceeds
the fluid-handling capacity of a dressing. In addition, repetitive
application and removal of adhesive tapes and dressings may
strip away the periwound stratum corneum, precipitating further
skin damage.
Periwound skin damage is not well documented, and the exact
prevalence of periwound skin damage remains elusive. Never-
theless, the impact of periwound skin damage is substantial.
One large-scale international survey involving 2018 patients with
chronic wounds found that 25% of respondents experienced
pain around the wound, likely from periwound skin damage
and local inflammatory responses.51 Woo et al2 also identified
that increased periwoundmaceration, a vestige of skin damage
from excessmoisture, is correlatedwith higher pain levels prior to
and during foam dressing changes. It is also acknowledged in the
literature that periwound skin damage may affect keratinocyte
migration fromwound edges to the wound base, delaying overall
wound healing.52,66
4. Peristomal Moisture-Associated Skin Damage
Peristomal MASD is characterized by inflammation and erosion
of the mucocutaneous junction and surrounding area.52,53 Despite
various containment strategies, fecal effluent may leak and spill
over to the peristomal skin, particularly in patients with hyperac-
tive bowels, diarrhea, and fistulas that connect the bowel and skin
surface. Undulating contour of the abdomen from excessive
subcutaneous fat, poor muscle tone, herniation, fissures (a linear
break in the skin with a dermal base), or crevices linked to skin/
muscle defects present challenges that often lead to poor appliance
adherence and pouch leakage.
Establishing a secure pouching system postmaceration is the
primary complication associated with peristomalMASD, because
it perpetuates a vicious cycle: Eroded epidermis produces mois-
ture that impedes the pouching system from adhering to the skin
and forming a tight seal, leading to further effluent-skin contact
that in turn causes greater maceration and pouching difficul-
ties.5,52,54,55 More than 50% of individuals with ostomies may
experience leakage, and the probability of developing peristomal
MASD over the life course for colostomates and ileostomates is
approximately 17.4% and 34%, respectively.56,57
The skin around a percutaneous endoscopic gastrostomy is also
at risk of MASD because of potential leakage of both digestive
enzymes (eg, bile salts, pancreatic lipases) and nutritional formula.58
For patients with tracheostomy, perspiration, saliva, or sputum
can accumulate around the stoma, under the flange of the external
cannula, and on the tracheostomy tie. Skin damage can be precip-
itated by inappropriate tube size/circumference and tracheostomy
dressing and change frequency.59,60 Unfortunately, none of the
studies examined the prevalence of skin damage in the tracheos-
tomy or gastrostomy areas.
Assessment of MASD
Incontinence-associated dermatitis typically presents as diffuse
erythema but may also be characterized by erosion, edema, scal-
ing, papules, or bullae containing serous exudate with accompa-
nying pruritus, burning, or pain.7,61 The Incontinence Associated
Dermatitis and Its Severity instrument is a novel tool that
assesses for redness, skin loss, and rash in the 13 body loca-
tions affected by IAD. A score of 0 to 52 is generated and used
to inform practice.62 Further, the Incontinence-Associated Der-
matitis Skin Condition Assessment Tool was developed by
Beeckman et al7 to describe the surface area (in centimeters
squared), severity of redness, and depth of any perineal skin
lesion.
More recently, a Global IAD Categorization tool was devel-
oped by an international expert panel and psychometrically tested
by 823 health professionals from 30 countries.63 The tool is simple
to use. First, the damaged skin is assessed to determine whether
persistent redness or skin loss is present. Next, clinical infection
or intertrigo is evaluated based on a cluster of signs and symp-
toms. As such, the IAD is classified into 4 categories: persistent
redness without clinical signs of infection, persistent redness
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with clinical signs of infection, skin loss without clinical signs
of infection, and persistent redness with clinical signs of
infection.
While ITD and IAD are precipitated by similar factors, ITD
affects other areas that are not affected by incontinence. Areas
affected by ITD can appear erythematous with scaling. Secondary
candida intertrigo is plausible based on the characteristic appear-
ance of satellite lesions. However, a validated measurement scale
to describe the severity of ITD is not available.
Periwound skin damage is evident from the varying degree
of skin maceration, erythema, edema, inflammation, blistering,
excoriation, and erosion. White maceration is when the skin ap-
pears white and swollen, and erythematous maceration is when
the skin is reddened and inflamed. Characteristic manifestations
of periwound skin damage include erosion, erythema, edema,
bleb formation, pruritus, edema, and pain.65 There are no stan-
dardized tools to measure or assess periwound skin damage.
Peristomal MASD is inflammation and erosion of the skin re-
lated to moisture that begins at the stoma/skin junction and may
extend outward.52 The Ostomy Skin Tool is designed to assess
the peristomal skin in 2 ways. First, it determines a score based
on discoloration, erosion, and tissue overgrowth. Pictorial refer-
ences are provided to aid the assessor. Second, the Ostomy Skin
Tool provides a diagnostic guide that directs the caregiver
through an interview with the patient to determine possible
causes of the skin disorder (eg, chemical irritation, mechanical
irritation, or infection).64
Management of MASD
1. Wash vulnerable skin with a gentle cleanser with minimal
rubbing. Avoid the use of soaps with an alkaline pH.
There is an increased bacterial count in the periwound skin
comparedwith normal skin.65Mechanical cleansing of periwound
skin can reduce the number of microorganisms not only on the
skin but also in the wound bed. The pH of healthy skin is approx-
imately 5 to 5.5, so when choosing a cleansing agent, it is pru-
dent to avoid alkaline products that can alter the pH of the skin
surface to amore basic environment promoting bacterial growth.66
Surfactant-based cleanser may be considered to help remove skin
debris such as water-insoluble proteins and lipids.
2. Use absorbent dressings for highly exudative wounds and
match dressing changes to exudate levels.
The importance of selecting an appropriate wound dressing for
protection against MASD is 2-fold: to support healing and pre-
vent further damage. An ideal dressing creates an optimal mois-
ture balance bymaintaining wound hydration while also keeping
damaging exudate away from the wound and periwound surface.
This balance requires a skillful and thoughtful selection of the
right dressing and frequency of changes.
Dressings are categorized according to their forms and func-
tions, especially in terms of absorbency and fluid-handling
capacity. Materials such as alginate, hydrofiber, polymers, and
foam are designed to handle large volume of fluid. The fluid-
handling capacity of various dressings may also be affected by
the polyurethane film backing and its ability to transfer moisture
vapor out of the dressing. Dressingsmay differ in their capacity to
lock in wound fluid, especially when pressure is applied, such as
with compression wraps.
It is ideal for a dressing to optimize vertical wicking (movement
of fluid into the dressing) while minimizing the risk of lateral
movement of fluid to periwound skin.67 If lateral wicking is antic-
ipated, the interface area where the dressing is appended to the
skin should be kept to a minimum by cutting the dressing down
to the size of the wound opening or selecting an appropriate
dressing size.
3. Use atraumatic tapes or adhesives.
Repeated application and removal of adhesive tapes and appli-
ances pull the skin surface from the epithelial cells, and this can
precipitate skin damage by stripping away the stratum corneum.2
In severe cases, erythema, edema, and blistering have been ob-
served. The periwound breakdown of surface keratin results in
local maceration and hyperhydration of the underlying epidermal
cells and dermal components.
As an alternative, dressings with silicone are superior in
preventing trauma. However, the silicone interface may create a
physical barrier that slows down fluid absorption, exposing the
skin to prolonged moisture. Take caution with patients who are
incontinent to avoid keeping soiled or saturated dressings in
direct contact with the skin.
4. Apply a barrier to vulnerable skin.
A plethora of treatments can protect the periwound skin, including
cyanoacrylate formulations, petrolatum- or silicone-based barrier
ointments, and polymer films that form on application through
solvent evaporation. These are available in squeezable tubes, sprays,
wipes, and/or vials.
The advantages and disadvantages of various skin barriers
are summarized in Table 1. Despite efficacy in protecting the
periwound tissue, variations in barrier formulation can affect sec-
ondary factors such as patient pain and sensitization. There is no
evidence that one barrier/protectant in the market is better than
any other; the performance of each product depends on the over-
all formulation and frequency of application, rather than on the
principal ingredient. However, Gray and Weir68 rank various
techniques for prevention of periwound maceration by the
strength of supporting evidence. Skin protectants such as
solvent-based polymer film barriers and zinc oxideYthickened
mechanical ointments are the only products to receive a score
of 1, indicating the highest level of supporting evidence.
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Petrolatum-based barrier ointments are popular for the
prevention and management of MASD. Petrolatum is a semi-
solid mixture of hydrocarbons that are hydrophobic (water re-
pelling). It tends to melt at a temperature of 37- C (99- F),
close to normal human body temperature. Intended to be a lu-
bricant, petrolatum can leave a greasy residue that prevents
adhesives and dressings from staying on periwound skin.
AzincoxideYbasedbarrier is another option. Zinc oxide is an
inorganic compound found in a variety of topical agents such as
powder, calamine cream, sunscreen, and shampoo. Zinc oxideY
based barriers coat and shield the skin from moisture and irri-
tants. It is not necessary to remove the barrier unless the material
is soiled; vigorous cleansing and rubbing can damage the fragile
and damaged skin.Depending on the formulation,metal oxide prep-
arationsmay also interfere with dressing absorption and adhesion.
Silicone-based barrier products have also been shown to be
effective in the protection andmanagement of periwound skin.29,51
Silicone consists of chains of hydrophobic polymers with alternat-
ingmolecules of silicone and oxygen. Recent formulationswith sil-
iconemay includemicronutrients and antioxidants, which seem to
benefit skin health based on the ability of such products to
prevent skin tears and reduce pressure ulceration.
Polymer filmbarrierpreparations.Organic solvent- or water-
based formulations that contain polymers can form barrier films
after application upon evaporation of the solvent.66 These poly-
mer barrier preparations, like petrolatum- and silicone-based
ointments, are well supported for prevention of maceration in
the periwound region.42,52,69Y71
Be careful when using polymer film barriers containing gum
mastic, a natural resin from the Pistacia lentiscus tree. There
have been reports of allergic skin reactions and irritant contact
dermatitis following application of barrier products containing
it. These adverse reactions to gum mastic have occurred when
product was applied after surgery, during patch testing, and to
secure catheters.72Y76
Alcohol was used as a solvent in many early formulations of
barrier films, and the introduction of no-sting alcohol-free prep-
arations has significantly reduced patient pain upon product
application.24,35,38,77 The no-sting preparations retain their efficacy;
in a study of 33 rehabilitation unit patients, maceration was
prevented in 94% of subjects, and skin stripping was absent in
all 33 subjects.77 In a double-blind study of 227 venous stasis
ulcer patients, a no-sting barrier film and water control were ap-
plied to opposing edges of the wound in each patient. In 97.3%
Table 1.
CLINICAL BARRIER OPTIONS FOR PROTECTION AGAINST MOISTURE-ASSOCIATED SKIN
DAMAGE
Product Category Advantages Disadvantages
Petrolatum-based barrier ointments
(a soft paraffin or wax mixture)
& Forms a seal over the skin to reduce transepidermal water loss;
optimal effect when applied to slightly dampened skin
& Petrolatum may melt under heat
& Thickening properties to protect against mechanical damage
and serve as a physical barrier against irritants
& May eave a greasy residue that interferes with
primary dressing adherence and absorption
& May build up in the pores and attract dirt and
bacteria, increasing the risk of folliculitis
Zinc oxideYthickened
petrolatum-containing barrier ointments
& Repels irritants in exudate, urine, and other fluids & Preparations may be thick and difficult to apply and
remove& Thickening properties to protect against mechanical damage
& May interfere with primary dressing adherence and
absorption
& Anti-inflammatory and antioxidant
& Ointment may inadvertently get into the wound and
interfere with antimicrobial ingredients
Silicone-based barrier ointments
(such as dimethicone)
& Dimethicone is permeable to water vapor that allows
evaporation of perspiration and minimizes the risk of miliaria
(heat rash)
& Thick ointments may interfere with primary dressing
adherence and absorption
& Conformable to periwound area or area of at risk skin
& Ointment may inadvertently get into the wound and
may not be indicated for use in open wounds
& Easy to spread and feels less greasy on skin
Film-forming polymers in water or
organic solvents
& Forms a mechanical barrier over periwound surface & Certain organic solvents may cause stinging and
irritation; also obvious inhalation and fire hazards& Thin and nonmessy
& Allows for adherence of wound dressing and protects against
skin stripping during dressing changes
& Much of the applied liquid evaporates, leaving a very
thin, insubstantial film compared with cyanoacrylates
Cyanoacrylate formulations & Creates a moisture-resistant barrier on skin & Cyanoacrylates are somewhat expensive raw
materials in skin barrier formulations& Protects against friction-induced skin damage
& Individuals may be allergic to cyanoacrylates& Does not require solvent, so all of the applied liquid turns into a
barrier
& Bonds to skin via polymerization in situ so very resistant to
wash off or premature removal
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of subjects, application of the barrier product controlled or re-
duced erythema as measured via a chromameter.78
Within the polymer film barriers, there is evidence suggesting
that organic solvent-free formulations provide greater protection
against skin trauma than equivalent solvent-containing formula-
tions.38 An RCT comparing 2 formulations, 1 with an organic sol-
vent base and 1 solvent-free formulation, was conducted on 12
human subjects. Adhesive tapewas applied to skin sections treated
with no product, solvent-free product, or solvent-containing
product. Stripping of the tape from the skin once a day over 5 days
was used to simulate skin trauma inflicted by dressing adhe-
sives in a clinical setting. Outcomesmeasuredwere site erythema
and transepidermal water loss (an established parameter of skin
microclimate and representative of the barrier properties of the
skin).79,80 Erythema, as evaluated by both an independent grader
and by a chromameter, was significantly reduced on skin treated
with the solvent-free barrier from day 4 onward. Water loss was
also reduced for skin treated with the solvent-free polymer. For
all 3 measures, the solvent-containing formulation provided
no more protection than no treatment at all, and the disparity
between the 2 formulations increased with repeated tape
stripping.38
Cyanoacrylates. A special class of acrylate polymer deriva-
tives has become available in recent years. These materials are
known generically as cyanoacrylates, or in common parlance,
“superglue.” Cyanoacrylates, or more accurately alkyl esters of
cyanoacrylates, are compounds that have an extra cyano group
attached to the acrylate portion of a molecule. This addition of
the cyano(-CN) chemical group to the acrylate moiety in the
film-forming monomer renders these compounds very sensitive
to moisture on skin, resulting in the formation of a flexible yet
tough film very quickly, within seconds, on the skin. The film that
forms on skin after application is a polymeric form of the mono-
meric cyanoacrylate that remains a liquid until it is delivered to
skin via an ampoule. Upon application, the monomeric liquid
begins rapid polymerization. The liquid is provided without sol-
vents, which eliminates the problems generally associated with
organic solvents such as inhalation hazards and fire risks. In
addition, this class of materials bonds chemically to the skin sur-
face as opposed to being deposited as a polymer film.
Cyanoacrylates seem to have a unique degree of robustness,
based on experience from clinicians who have written on the
skin protective aspect of these materials.22,39 A case series by
Milne et al,22 for example, has discussed the successful use of
a cyanoacrylate protectant in the skin management of peristomal
irritant dermatitis and superficial skin lesions in residents in acute
care and outpatient settings. The cyanoacrylate protectant is
supplied in unit-dose ampoules and has a purple tint that allows
clinicians to identify the area where the liquid barrier is applied to
avoid excessive application. The barrier is shed naturally from the
skin surface as the stratum corneum sloughs off, and this
sloughing off is easilymonitored by the gradual fading of the pur-
ple tint. Experience shows that once bonded to skin, exposure to
body fluids or washing or soaping with water will not eliminate
the product from skin for 24 to 72 hours, which demonstrates the
ability of the chemical bond of the cyanoacrylate product to the
underlying skin to resist external insult from environmental
agents.40 The concentration of the cyanoacrylate could matter,
because cyanoacrylates that are formulated with diluting solvents
will tend to produce a thinner and less robust protective film.
5. Treat skin infection and dermatitis.
Patients with chronic wounds are exposed to a plethora of po-
tential contact irritants and allergens, leading to dermatitis. The
best approach to dermatitis is to treat the trigger or cause, address
secondary infection, and then use topical steroids for the inflam-
matory component. Although moisture-wicking fabric may be
useful for the management of moisture in skin folds, the effec-
tiveness for the prevention and treatment of ITD remains unclear.
6. Regularly assess skin around wounds and areas that are sus-
ceptible to moisture damage.
Although there are a number of tools that have been developed
to describe wound status, none of the tools address periwound
skin condition. The Bates-JensenWound Status Tool instructs cli-
nicians to document wound edges and skin surrounding the
wound in terms of discoloration. To provide a comprehensive as-
sessment of periwound skin, it is recommended that the skin is
evaluated and assessed formaceration, erythema, and erosion re-
lated to MASD.
7. Promote optimal skin health.
The stratum corneum normally has 10% to 15% moisture con-
tent. While excessive moisture is damaging, dry skin is prone to
superficial breaks leading to scaling, flaking, and fissuring,
allowing irritants to penetrate into deep skin structures. In severe
cases, xerotic areas are characterized by intense irritation, inflam-
mation, and itchiness. Natural moisturizing factors are found in
the stratum corneum. They are humectants that can rehydrate
skin because of their hydroscopic property to attract and bindwater
molecules from the atmosphere, donating it into the corneocytes.
Replenishing natural moisturizing factors and humectants can be
accomplished through the application of moisturizers containing
amino acids such as pyrrolidone carboxylic acid, urocanic acid, pro-
pylene glycol (glycerine), lactic acid, and urea. Other ingredients
that should be considered to promote healthy skin are ceramides
(the major lipid constituent in the intercellular spaces of the
stratum corneum), essential fatty acids such as linoleic acid that
may modulate inflammatory and immune responses in the
skin, vitamins, and antioxidants to combat against damaging
effects of reactive oxygen species radicals.
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CONCLUSIONS
Moisture can induce significant damage in the skin folds, per-
ineum, and areas surrounding a wound or stoma comprising
the skin’s normal function as a barrier. Protection of the skin
against moisture damage is an important component of com-
prehensive skin and wound care. Based on this scoping review
of literature, the authors propose key interventions to protect
and prevent MASD including the use of barrier ointments, liq-
uid polymers, and cyanoacrylates, which can be applied on the
periwound region to create a protective layer that simulta-
neously maintains hydration levels while blocking external
sources of moisture and irritants. There is a need for additional
studies to validate existing and emerging technologies for the
management of MASD in various clinical settings and patient
populations.&
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